Navigation Links
Trial of new treatment for advanced melanoma shows rapid shrinking of tumors
Date:9/23/2009

a cancer meeting earlier this year (ASCO 2009). These data had been aimed at finding the best dose of PLX4032 to give to patients. However, the phase I extension data reported at ECCO 15 ESMO 34 focuses on a subsequent group of an additional 31 patients who were all treated at the maximum tolerated dose of the drug (a 960 mg pill twice a day). All the patients had the BRAF mutation.

Dr Chapman said: "What makes this treatment different from standard chemotherapy is that standard chemotherapy attacks the machinery involved in cell division; so to stop the cancer cells dividing uncontrollably, most standard chemotherapy aims to block the mechanism of division by interfering directly with DNA replication or with microtubules in the dividing cells. PLX4302 is different because it attacks the genetic programme that is causing the cells to divide uncontrollably, and we think the BRAF mutation is driving that programme. The drug is blocking the genetics of the tumour, rather than trying to interfere with the proliferation of the cells and, as a result, there are fewer side effects, although there are some. We are seeing some pretty dramatic and rapid responses, and they are occurring in sites where we rarely see responses to chemotherapy, such as in the bone.

"There are some important caveats. All these patients had failed previous therapies, either chemotherapy or treatment with Interleukin 2, as well as surgery. However, we know that only 10-30% of patients will respond to standard chemotherapy, so it's not surprising that our patients had not responded, or have responded and then the cancer has recurred. In our study 64% of patients have had a partial response, but because we are only treating patients with the BRAF mutation, we are cutting out about 40% of melanoma patients who do not have this mutation and whom we know will not respond to this treatment. That is one reason why we are seeing a much higher response than with conventional treatments.
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
2. World-first swine-flu vaccine trial reveals one dose provides strong immune response
3. This idea doesnt stink: New tech cuts industrial odors, pollutants
4. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
5. Britains first swine-flu trials under way
6. Extraterrestrial platinum was stirred into the Earth
7. First genetically-engineered malaria vaccine to enter human trials
8. Results from trials of DHA in Alzheimers disease and age-related cognitive decline
9. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
10. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
11. Enzyme doesnt act alone in atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , August 22, 2014 ... ) has announced the addition of ... 2014-2018"  report to their offering.  ... ,Biometrics is a technology that helps ... on their physical or behavioral features. ...
(Date:8/22/2014)... RIVERSIDE, Calif. Thomson Reuters , a leading ... five researchers at the University of California, Riverside in ... brightest minds of our times." , To generate the ... (2002-2012) to identify researchers whose published work has had ... included among some 3,200 individuals who published the greatest ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... Inc. (Nasdaq: AWRE ), a leading supplier of ... to discuss the company,s operating results for the fourth quarter ... 5:00 p.m. Eastern Time. CEO Michael Tzannes and CFO Rick ... webcast by Thomson and can be accessed on the Investor ...
... the potentially fatal hepatitis C virus has banked its ... inability to infect animals other than humans and chimpanzees ... animal model for the disease. But now, in a ... online issue of Nature , Rockefeller University scientists ...
... . , Lack of sleep is a ... the day poses a very real and dangerous problem. ... at McGill University demonstrates interestingly, that sleep-wake states are ... melanin-concentrating hormone (MCH) neurons and orexin (Orx) neurons, which ...
Cached Biology News:Aware Announces Q4 and FY2008 Earnings Conference Call 2Discovery could lead to a new animal model for hepatitis C 2What happens when we sleep 2
(Date:8/22/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... on the current state of the Papain industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) filed a ... for the D.C. Circuit challenging the FAA’s Interpretation of the ... on June 25, 2014. , The AMA believes that ... intent of the FAA Modernization and Reform Act of 2012, ... new rules or regulations regarding model aircraft that are operated ...
(Date:8/22/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... 30, 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have ... June 30, , Six-months ended June 30, ( ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 ...
(Date:8/22/2014)... of Surrey have discovered how the receptors responsible for ... , The new study, published today in The ... in turn regulates the cycle of all cells in ... the local biological clock and its control are weakened ... in bladder physiology and ageing. , While ...
Breaking Biology Technology:Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2
... Sept. 6, 2011 The Immune Deficiency Foundation (IDF) ... continuing education (CE) course for  nurses. The goal of ... nurses by providing an educational update on primary immunodeficiency ... is the national patient organization dedicated to improving the ...
... 6, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... safety update following 17 months of post-approval use in ... Dupuytren,s contracture patients with a palpable cord.  After approximately ... U.S., there was no clinically meaningful change in the ...
... Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today ... will be branded as Oncoprex™ .   ... oncology sector in recognition of our advancing development programs.  We ... to unlock the unrealized potential of a growing list of ...
Cached Biology Technology:Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 2Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... measurements in an easy-to-use benchtop package. ... spectrometer (ESI-oa-TOF) concentrates the performance of ... which fits on your bench. The ... 10,000 FWHM and mass accuracy of ...
... The lower cost and reduced ... system make reference standard DNA analysis ... be used with any of SEQUENOM's ... High-Performance Genotyping (iPLEXTM Gold) , Gene ...
... jetSI-ENDO-FluoR is a tetramethylrhodamine-conjugated jetSI-ENDO ... at 580 nm), the powerful ... are used to determine the ... intracellular delivery and trafficking of ...
Biology Products: